News | Heart Valve Technology | November 07, 2016

Delirium Significantly Associated With Brain Lesions in Patients Post-TAVR

Data highlight need for brain protection during cardiovascular procedures

TAVR, post-procedure, brain lesions, delirium, TCT 2016, Peter R. Stella

November 7, 2016 — Keystone Heart Ltd. announced that data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium demonstrate an increase in brain lesions for patients following transcatheter aortic valve replacement (TAVR) procedures, which were significantly associated with delirium.

"It is imperative that we take steps toward preventing damage to the brain during TAVR," said Peter R. Stella, M.D., Ph.D., Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands, who led the study. "These results clearly demonstrate that the quality of life for patients undergoing TAVR can deteriorate substantially if the brain is not protected, and to date the guidelines do not suggest that we need to take any precautions."

Watch the VIDEO “Defining the Need for TAVR Embolic Protection.”

In the study, 90 percent of patients (n=103) undergoing TAVR demonstrated lesions in the brain following TAVR procedure, based on evaluation using diffusion weighted magnetic resonance imaging (DW-MRI).  Of these, 14.5 percent (n=15) were identified as having post-operative delirium (POD) using the Delirium Observational Scale based on Diagnostic and Statistical Manual of Mental Disorder, 4th Edition criteria.

The number of new cerebral DWI-lesions was higher in patients with POD (8[5-15] vs.4 [2-7], p=0.023). After controlling for several confounding factors (e.g., global cortical atrophy, white matter abnormalities, logistic EuroSCORE, access site), the number of DWI-lesions significantly associated with POD remained higher (Odds Ratio 1.08; 95 percent confidence interval 1.10-1.16, per number of DWI-lesions increase).

Post-op delirium in TAVR patients has been shown to lead to a three-fold increase in both post-procedural and long-term mortality, according to previously published data (Giuseffi JL, J Am Coll Cardiol. 2014;63:12, Abawi M, J Am Coll Cardiol Intv. 2016;9:160.) Other studies have also shown that post-op delirium can lead to extended length of stay and in-hospital complications, as well as an increase in healthcare costs of between $16,000 to $64,000 per patient (Leslie DL, J Am Geriatr Soc. 2011;59:S241).

Numerous other studies conducted in Europe laid the groundwork for these findings, with their data demonstrating that 58-100 percent of patients have new brain lesions following TAVR. The recently published NeuroTAVR  study, conducted out of Yale, shows that 94 percent of patients (n=44) had new lesions in the brain following the TAVR procedure, 22.6 percent of patients had new neurologic impairment post-TAVR, and 41 percent of patients had declining neurocognition at 30 days when compared to pre-TAVR scores in the United States.

Data presented as part of PCR London Valves 2016 by Alexandra J. Lansky, M.D., Division of Cardiology, Yale School of Medicine and Yale Cardiovascular Research Group, New Haven, Conn., demonstrated the safety and efficacy of the TriGuard Cerebral Embolic Protection device when used during TAVR. Use of the device, which provides protection for all three arteries that provide blood flow to the brain, showed significant reduction of all stroke and neurologic decline. According to preliminary findings from this real-world experience from University Medical Centre Utrecht, Utrecht, The Netherlands and Hamburg University Cardiovascular Center and Department of Structural Heart Disease, Hamburg, Germany, no patients had strokes with TriGuard protection and in a subgroup of patients with DW-MRI, only 20 percent of patients had new lesions compared to close to 70 percent of patients without embolic protection.

Read the article, “TAVR Embolic Protection Did Not Reduce Emboli Brain Lesions.” This is for a second trial presented at TCT for a TAVR embolic protection system, but data was not that positive for the Claret Medical’s Sentinel transcatheter cerebral embolic protection system. 

For more information: www.crf.org/tct

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th